AbbVie Inc (ABBV)vs10X Genomics Inc (TXG)
ABBV
AbbVie Inc
$227.23
-2.69%
HEALTHCARE · Cap: $380.57B
TXG
10X Genomics Inc
$31.04
-7.34%
HEALTHCARE · Cap: $3.66B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 9734% more annual revenue ($62.82B vs $638.78M). ABBV leads profitability with a 5.8% profit margin vs -3.5%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TXG
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+68.7%
Fair Value
$61.17
Current Price
$31.04
$30.13 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Weak financial health signals
ROE of -2.8% — below average capital efficiency
Revenue declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : TXG
The strongest argument for TXG centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : TXG
The primary concerns for TXG are EPS Growth, Piotroski F-Score, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while TXG is a turnaround play — different risk/reward profiles.
TXG carries more volatility with a beta of 2.11 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100) and 12.4% revenue growth. TXG offers better value entry with a 68.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
10X Genomics Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?